Custom Recombinant Antibody Conversion Service - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512242177

Publication Date:

December 11, 2024

Pages:

159

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Computing & Electronics [3]

Description:

The global market for Custom Recombinant Antibody Conversion Service was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Custom Recombinant Antibody Conversion Service was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Custom Recombinant Antibody Conversion Service was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Custom Recombinant Antibody Conversion Service was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Custom Recombinant Antibody Conversion Service include Creative Biolabs, Abnova Corporation, GenScript Biotech Corporation, Bio-Rad Laboratories, Thermo Fisher Scientific, Covance Inc., Rockland Immunochemicals Inc., LakePharma Inc. and ProteoGenix, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Custom Recombinant Antibody Conversion Service, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Custom Recombinant Antibody Conversion Service by region & country, by Type, and by Application.
The Custom Recombinant Antibody Conversion Service market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Custom Recombinant Antibody Conversion Service.
麻豆原创 Segmentation
By Company
Creative Biolabs
Abnova Corporation
GenScript Biotech Corporation
Bio-Rad Laboratories
Thermo Fisher Scientific
Covance Inc.
Rockland Immunochemicals Inc.
LakePharma Inc.
ProteoGenix
ProMab Biotechnologies Inc.
Sino Biological Inc.
BOC Sciences
Antitope Limited
Absolute Antibody Ltd.
Genscript USA Inc.
OriGene Technologies Inc.
Fitzgerald Industries International
Novus Biologicals LLC
BioLegend Inc.
RayBiotech Inc.
Proteintech Group Inc.
ACROBiosystems
Atlas Antibodies AB
Agilent Technologies
Molecular Innovations Inc.
Segment by Type:
Fab and scFv Antibody Fragment Production
Chimeric Antibody Production
Bispecific Antibody Production
Antibody Labeling and Conjugation
Segment by Application
Research and Development
Diagnostics
Therapeutics
Biomanufacturing
Agriculture and Food
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Custom Recombinant Antibody Conversion Service manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Custom Recombinant Antibody Conversion Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Custom Recombinant Antibody Conversion Service in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Custom Recombinant Antibody Conversion Service Product Introduction
1.2 Global Custom Recombinant Antibody Conversion Service 麻豆原创 Size Forecast
1.3 Custom Recombinant Antibody Conversion Service 麻豆原创 Trends & Drivers
1.3.1 Custom Recombinant Antibody Conversion Service Industry Trends
1.3.2 Custom Recombinant Antibody Conversion Service 麻豆原创 Drivers & Opportunity
1.3.3 Custom Recombinant Antibody Conversion Service 麻豆原创 Challenges
1.3.4 Custom Recombinant Antibody Conversion Service 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Custom Recombinant Antibody Conversion Service Players Revenue Ranking (2023)
2.2 Global Custom Recombinant Antibody Conversion Service Revenue by Company (2019-2024)
2.3 Key Companies Custom Recombinant Antibody Conversion Service Manufacturing Base Distribution and Headquarters
2.4 Key Companies Custom Recombinant Antibody Conversion Service Product Offered
2.5 Key Companies Time to Begin Mass Production of Custom Recombinant Antibody Conversion Service
2.6 Custom Recombinant Antibody Conversion Service 麻豆原创 Competitive Analysis
2.6.1 Custom Recombinant Antibody Conversion Service 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Custom Recombinant Antibody Conversion Service Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Custom Recombinant Antibody Conversion Service as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Fab and scFv Antibody Fragment Production
3.1.2 Chimeric Antibody Production
3.1.3 Bispecific Antibody Production
3.1.4 Antibody Labeling and Conjugation
3.2 Global Custom Recombinant Antibody Conversion Service Sales Value by Type
3.2.1 Global Custom Recombinant Antibody Conversion Service Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Custom Recombinant Antibody Conversion Service Sales Value, by Type (2019-2030)
3.2.3 Global Custom Recombinant Antibody Conversion Service Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Research and Development
4.1.2 Diagnostics
4.1.3 Therapeutics
4.1.4 Biomanufacturing
4.1.5 Agriculture and Food
4.1.6 Others
4.2 Global Custom Recombinant Antibody Conversion Service Sales Value by Application
4.2.1 Global Custom Recombinant Antibody Conversion Service Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Custom Recombinant Antibody Conversion Service Sales Value, by Application (2019-2030)
4.2.3 Global Custom Recombinant Antibody Conversion Service Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Custom Recombinant Antibody Conversion Service Sales Value by Region
5.1.1 Global Custom Recombinant Antibody Conversion Service Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Custom Recombinant Antibody Conversion Service Sales Value by Region (2019-2024)
5.1.3 Global Custom Recombinant Antibody Conversion Service Sales Value by Region (2025-2030)
5.1.4 Global Custom Recombinant Antibody Conversion Service Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
5.2.2 North America Custom Recombinant Antibody Conversion Service Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
5.3.2 Europe Custom Recombinant Antibody Conversion Service Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
5.4.2 Asia Pacific Custom Recombinant Antibody Conversion Service Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
5.5.2 South America Custom Recombinant Antibody Conversion Service Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
5.6.2 Middle East & Africa Custom Recombinant Antibody Conversion Service Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Custom Recombinant Antibody Conversion Service Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Custom Recombinant Antibody Conversion Service Sales Value
6.3 United States
6.3.1 United States Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
6.3.2 United States Custom Recombinant Antibody Conversion Service Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Custom Recombinant Antibody Conversion Service Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
6.4.2 Europe Custom Recombinant Antibody Conversion Service Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Custom Recombinant Antibody Conversion Service Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
6.5.2 China Custom Recombinant Antibody Conversion Service Sales Value by Type (%), 2023 VS 2030
6.5.3 China Custom Recombinant Antibody Conversion Service Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
6.6.2 Japan Custom Recombinant Antibody Conversion Service Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Custom Recombinant Antibody Conversion Service Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
6.7.2 South Korea Custom Recombinant Antibody Conversion Service Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Custom Recombinant Antibody Conversion Service Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
6.8.2 Southeast Asia Custom Recombinant Antibody Conversion Service Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Custom Recombinant Antibody Conversion Service Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Custom Recombinant Antibody Conversion Service Sales Value, 2019-2030
6.9.2 India Custom Recombinant Antibody Conversion Service Sales Value by Type (%), 2023 VS 2030
6.9.3 India Custom Recombinant Antibody Conversion Service Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Creative Biolabs
7.1.1 Creative Biolabs Profile
7.1.2 Creative Biolabs Main Business
7.1.3 Creative Biolabs Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.1.4 Creative Biolabs Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.1.5 Creative Biolabs Recent Developments
7.2 Abnova Corporation
7.2.1 Abnova Corporation Profile
7.2.2 Abnova Corporation Main Business
7.2.3 Abnova Corporation Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.2.4 Abnova Corporation Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.2.5 Abnova Corporation Recent Developments
7.3 GenScript Biotech Corporation
7.3.1 GenScript Biotech Corporation Profile
7.3.2 GenScript Biotech Corporation Main Business
7.3.3 GenScript Biotech Corporation Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.3.4 GenScript Biotech Corporation Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.3.5 Bio-Rad Laboratories Recent Developments
7.4 Bio-Rad Laboratories
7.4.1 Bio-Rad Laboratories Profile
7.4.2 Bio-Rad Laboratories Main Business
7.4.3 Bio-Rad Laboratories Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.4.4 Bio-Rad Laboratories Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.4.5 Bio-Rad Laboratories Recent Developments
7.5 Thermo Fisher Scientific
7.5.1 Thermo Fisher Scientific Profile
7.5.2 Thermo Fisher Scientific Main Business
7.5.3 Thermo Fisher Scientific Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.5.4 Thermo Fisher Scientific Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.5.5 Thermo Fisher Scientific Recent Developments
7.6 Covance Inc.
7.6.1 Covance Inc. Profile
7.6.2 Covance Inc. Main Business
7.6.3 Covance Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.6.4 Covance Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.6.5 Covance Inc. Recent Developments
7.7 Rockland Immunochemicals Inc.
7.7.1 Rockland Immunochemicals Inc. Profile
7.7.2 Rockland Immunochemicals Inc. Main Business
7.7.3 Rockland Immunochemicals Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.7.4 Rockland Immunochemicals Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.7.5 Rockland Immunochemicals Inc. Recent Developments
7.8 LakePharma Inc.
7.8.1 LakePharma Inc. Profile
7.8.2 LakePharma Inc. Main Business
7.8.3 LakePharma Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.8.4 LakePharma Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.8.5 LakePharma Inc. Recent Developments
7.9 ProteoGenix
7.9.1 ProteoGenix Profile
7.9.2 ProteoGenix Main Business
7.9.3 ProteoGenix Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.9.4 ProteoGenix Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.9.5 ProteoGenix Recent Developments
7.10 ProMab Biotechnologies Inc.
7.10.1 ProMab Biotechnologies Inc. Profile
7.10.2 ProMab Biotechnologies Inc. Main Business
7.10.3 ProMab Biotechnologies Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.10.4 ProMab Biotechnologies Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.10.5 ProMab Biotechnologies Inc. Recent Developments
7.11 Sino Biological Inc.
7.11.1 Sino Biological Inc. Profile
7.11.2 Sino Biological Inc. Main Business
7.11.3 Sino Biological Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.11.4 Sino Biological Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.11.5 Sino Biological Inc. Recent Developments
7.12 BOC Sciences
7.12.1 BOC Sciences Profile
7.12.2 BOC Sciences Main Business
7.12.3 BOC Sciences Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.12.4 BOC Sciences Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.12.5 BOC Sciences Recent Developments
7.13 Antitope Limited
7.13.1 Antitope Limited Profile
7.13.2 Antitope Limited Main Business
7.13.3 Antitope Limited Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.13.4 Antitope Limited Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.13.5 Antitope Limited Recent Developments
7.14 Absolute Antibody Ltd.
7.14.1 Absolute Antibody Ltd. Profile
7.14.2 Absolute Antibody Ltd. Main Business
7.14.3 Absolute Antibody Ltd. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.14.4 Absolute Antibody Ltd. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.14.5 Absolute Antibody Ltd. Recent Developments
7.15 Genscript USA Inc.
7.15.1 Genscript USA Inc. Profile
7.15.2 Genscript USA Inc. Main Business
7.15.3 Genscript USA Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.15.4 Genscript USA Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.15.5 Genscript USA Inc. Recent Developments
7.16 OriGene Technologies Inc.
7.16.1 OriGene Technologies Inc. Profile
7.16.2 OriGene Technologies Inc. Main Business
7.16.3 OriGene Technologies Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.16.4 OriGene Technologies Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.16.5 OriGene Technologies Inc. Recent Developments
7.17 Fitzgerald Industries International
7.17.1 Fitzgerald Industries International Profile
7.17.2 Fitzgerald Industries International Main Business
7.17.3 Fitzgerald Industries International Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.17.4 Fitzgerald Industries International Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.17.5 Fitzgerald Industries International Recent Developments
7.18 Novus Biologicals LLC
7.18.1 Novus Biologicals LLC Profile
7.18.2 Novus Biologicals LLC Main Business
7.18.3 Novus Biologicals LLC Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.18.4 Novus Biologicals LLC Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.18.5 Novus Biologicals LLC Recent Developments
7.19 BioLegend Inc.
7.19.1 BioLegend Inc. Profile
7.19.2 BioLegend Inc. Main Business
7.19.3 BioLegend Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.19.4 BioLegend Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.19.5 BioLegend Inc. Recent Developments
7.20 RayBiotech Inc.
7.20.1 RayBiotech Inc. Profile
7.20.2 RayBiotech Inc. Main Business
7.20.3 RayBiotech Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.20.4 RayBiotech Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.20.5 RayBiotech Inc. Recent Developments
7.21 Proteintech Group Inc.
7.21.1 Proteintech Group Inc. Profile
7.21.2 Proteintech Group Inc. Main Business
7.21.3 Proteintech Group Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.21.4 Proteintech Group Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.21.5 Proteintech Group Inc. Recent Developments
7.22 ACROBiosystems
7.22.1 ACROBiosystems Profile
7.22.2 ACROBiosystems Main Business
7.22.3 ACROBiosystems Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.22.4 ACROBiosystems Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.22.5 ACROBiosystems Recent Developments
7.23 Atlas Antibodies AB
7.23.1 Atlas Antibodies AB Profile
7.23.2 Atlas Antibodies AB Main Business
7.23.3 Atlas Antibodies AB Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.23.4 Atlas Antibodies AB Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.23.5 Atlas Antibodies AB Recent Developments
7.24 Agilent Technologies
7.24.1 Agilent Technologies Profile
7.24.2 Agilent Technologies Main Business
7.24.3 Agilent Technologies Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.24.4 Agilent Technologies Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.24.5 Agilent Technologies Recent Developments
7.25 Molecular Innovations Inc.
7.25.1 Molecular Innovations Inc. Profile
7.25.2 Molecular Innovations Inc. Main Business
7.25.3 Molecular Innovations Inc. Custom Recombinant Antibody Conversion Service Products, Services and Solutions
7.25.4 Molecular Innovations Inc. Custom Recombinant Antibody Conversion Service Revenue (US$ Million) & (2019-2024)
7.25.5 Molecular Innovations Inc. Recent Developments
8 Industry Chain Analysis
8.1 Custom Recombinant Antibody Conversion Service Industrial Chain
8.2 Custom Recombinant Antibody Conversion Service Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Custom Recombinant Antibody Conversion Service Sales Model
8.5.2 Sales Channel
8.5.3 Custom Recombinant Antibody Conversion Service Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Creative Biolabs
Abnova Corporation
GenScript Biotech Corporation
Bio-Rad Laboratories
Thermo Fisher Scientific
Covance Inc.
Rockland Immunochemicals Inc.
LakePharma Inc.
ProteoGenix
ProMab Biotechnologies Inc.
Sino Biological Inc.
BOC Sciences
Antitope Limited
Absolute Antibody Ltd.
Genscript USA Inc.
OriGene Technologies Inc.
Fitzgerald Industries International
Novus Biologicals LLC
BioLegend Inc.
RayBiotech Inc.
Proteintech Group Inc.
ACROBiosystems
Atlas Antibodies AB
Agilent Technologies
Molecular Innovations Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.